Cancer Progression Is not Different in Mice of Different Gender Inoculated With Cells of the Triple-Negative 4T1 Breast Cancer Model

Background Breast cancer in men is a rare and poorly studied disease, and its treatment is based on women breast cancer studies. However, clinical outcome is not the same in men and women. Basic studies and clinical trials in animal models provide detailed information on cancer, origin, development, cell signaling pathways, sites of metastasis, and target molecules. It is necessary to explore the biology of breast cancer in male animal models that allow observing their similarity. Methods The triple-negative 4T1 breast cancer model was developed in both male and female mice and studied weekly during 4 weeks. For that, twenty 8-week-old female and male BALB/c mice were used. Sixteen mice (eight males and eight females) were inoculated into the second left thoracic mammary pad with 20,000 4T1 cells, resuspended in 20 µL phosphate-buffered saline (PBS). All samples were processed for immunodetection, characterized histopathologically and immunohistochemically. Results In this work, we describe the development of a triple-negative 4T1 breast cancer model in male BALB/c mice. Breast tumors were characterized histopathologically at different time points and corresponded to a moderately differentiated invasive ductal carcinoma, estrogen receptor ER-/progesterone receptor PR-/human epidermal growth factor receptor 2 HER2-/Ki67+, with histological grade II (moderately differentiated; a solid mass with occasional duct formation and moderate to severe nuclear pleomorphism), infiltrating the adipose and muscular tissue, and metastasis to lungs. From the results, we did not observe differences in the time of tumor development, necrosis, color change of tumor tissue, and lung metastasis between male and female mice. Even though we did not find histological differences, response to treatment and molecular signaling may be different. Conclusions The histogenesis of male breast tumors was similar to that of female BALB/c mice. The histological and immunohistochemical characteristics of male tumors also match the features reported for stage IV human breast cancer of men and women. The murine male breast cancer model described here can be a significant tool to explore the molecular mechanisms involved in male breast cancer tumorigenesis and metastasis and may bring new approaches for clinical treatment of triple-negative breast cancer in men.

[1]  N. Yao,et al.  Clinicopathologic characteristics and prognosis for male breast cancer compared to female breast cancer , 2022, Scientific reports.

[2]  K. Takabe,et al.  Management of Male Breast Cancer: The Journey so Far and Future Directions , 2021, World journal of oncology.

[3]  Y. Tao,et al.  Characteristics of male triple negative breast cancer: A population‐based study , 2020, The breast journal.

[4]  I. Okano,et al.  Orthotopic Implantation Achieves Better Engraftment and Faster Growth Than Subcutaneous Implantation in Breast Cancer Patient-Derived Xenografts , 2020, Journal of Mammary Gland Biology and Neoplasia.

[5]  Kimberly J. Johnson,et al.  Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis , 2018, Clinical breast cancer.

[6]  Melissa P. Murray,et al.  Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  B. Foster,et al.  Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research , 2017, Journal of Mammary Gland Biology and Neoplasia.

[8]  Ana C. Gregório,et al.  Inoculated Cell Density as a Determinant Factor of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine Model , 2016, PloS one.

[9]  Kebin Liu,et al.  An Orthotopic Mouse Model of Spontaneous Breast Cancer Metastasis. , 2016, Journal of visualized experiments : JoVE.

[10]  E. Shahverdi,et al.  A Review of the Clinical Implications of Breast Cancer Biology , 2016, Electronic physician.

[11]  K. Takabe,et al.  Animal models for exploring the pharmacokinetics of breast cancer therapies , 2015, Expert opinion on drug metabolism & toxicology.

[12]  K. Sainis,et al.  F1 hybrids of BALB/c and C57BL/6 mouse strains respond differently to low-dose ionizing radiation exposure , 2014, Journal of Genetics.

[13]  S. Milstien,et al.  An improved syngeneic orthotopic murine model of human breast cancer progression , 2014, Breast Cancer Research and Treatment.

[14]  G. M. Nagaraja,et al.  A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease , 2012, BMC Cancer.

[15]  Joseph,et al.  Imagable 4T1 model for the study of late stage breast cancer , 2008, BMC Cancer.

[16]  Helen Swede,et al.  Epidemiology of male breast cancer. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  E. Richtig,et al.  Calculated tumour volume as a prognostic parameter for survival in choroidal melanomas , 2004, Eye.

[18]  S. Ostrand-Rosenberg,et al.  Mouse 4T1 Breast Tumor Model , 2000, Current protocols in immunology.

[19]  I. Ellis,et al.  A comparison outcome of male breast cancer with female breast cancer. , 1997, American journal of surgery.

[20]  Ali Jad Abdelwahab Yousef Male Breast Cancer: Epidemiology and Risk Factors. , 2017, Seminars in oncology.